Rectal AdenocarcinomaPhase 2ULTIMATENCT07209215
ctDNA-Informed Management of Early-Stage Rectal Cancer
A Phase 2 study testing Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT) in people with Rectal Adenocarcinoma and Rectal Cancer, run by University of California, Davis at 1 site in United States.
Trial summary
This is a phase 2 pragmatic study to examine the utility of ctDNA-informed treatment management for participants with early-stage rectal cancer using the Signatera Genome assay. The primary aims are to 1) assess pathologic complete response (path CR) in the ctDNA informed management arm; 2) assess pathologic complete… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Rectal Adenocarcinoma, Rectal Cancer, Early-stage Rectal Cancer
- What is being tested?
- Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteUnited States
- Study dates
- Oct 2026to Dec 2028
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Tumor tissue histologically confirming rectal adenocarcinoma that is available for Natera ctDNA assay.
- Cohort A only: Patients appropriate for receiving TNT including chemotherapy and chemoradiation.
- Cohort B only: TNT must have included at least 4 cycles of CAPEOX or 6 cycles of FOLFOX and at least 45 Gy in 25 fractions to the pelvis during chemoradiation.
- Patients ≥18 years of age at time of consent.
- Ability to understand and willingness to sign the informed consent form (ICF).
- Ability and stated willingness to adhere to the study visit schedule and protocol procedures/requirements.
Who cannot join
- Prior treatment for rectal cancer, except for cohort B.
- Evidence of distant metastatic disease on staging imaging (CT chest with abdominopelvic imaging by CT or MRI) within 8 weeks of enrollment.
- Patients on hemodialysis.
- Any condition that in the opinion of the investigator would interfere with the participant's safety or compliance while on trial
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817
Office of Clinical Research, 916-382-6970, OCRReferral@health.ucdavis.edu
About this study
Official title: ULtra sensiTive ctDNA-Informed Management eArly-stage recTal cancEr (ULTIMATE)
This is a phase 2 pragmatic study to examine the utility of ctDNA-informed treatment management for participants with early-stage rectal cancer using the Signatera Genome assay. The primary aims are to 1) assess pathologic complete response (path CR) in the ctDNA informed management arm; 2) assess pathologic complete response (path CR) in the post total neoadjuvant therapy (TNT) standard of care (SOC) surgery arm; and 3) assess disease free survival (DFS) in the ctDNA informed management arm.
Read the detailed description
Two cohorts of participants will be enrolled: Cohort A (participants appropriate for receiving TNT) and Cohort B (TNT already performed at UC Davis Health or externally). At Time A after TNT is completed and based on ctDNA assay results, the clinical decision will be made to put participants into one of two arms: the ctDNA informed management arm (Watchful Waiting [WW] surveillance) or the post TNT SOC surgery arm; participants will be monitored for ctDNA positivity for up to 5 years.
- Conditions
- Rectal Adenocarcinoma, Rectal Cancer, Early-stage Rectal Cancer, Locally Advanced Rectal Adenocarcinoma
- Being tested
- Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT)
- Medical subject headings
- Rectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT)Drug
Use of Signatera Genome ultra-sensitive ctDNA blood test post-total neoadjuvant therapy (TNT) for ctDNA-informed treatment management of early-stage rectal cancer.
| Study group | Role | What they receive |
|---|---|---|
| ctDNA informed management arm (Watch and Wait surveillance) | Experimental | Not described Receives: Drug: Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT) |
| Post TNT SOC surgery arm | Experimental | Not described Receives: Drug: Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pathologic complete response (pathCR) rate (ctDNA Informed Management Arm)
Percent of participants with local regrowth within 2 years of total neoadjuvant therapy (TNT)
Measured: Up to 2 years after TNT
Pathologic complete response (pathCR) rate (Post TNT SOC Surgery Arm)
Percent of participants with local regrowth within 2 years of TNT
Measured: Up to 2 years after TNT
Disease-free survival (DFS) rate (ctDNA Informed Management Arm)
Median interval from first date of TNT to the first occurrence of locoregional failure, distant recurrence, a new invasive colorectal primary cancer.
Measured: Up to 2 years after TNT
Secondary outcomes (1)
Frequency of local regrowth (ctDNA Informed Management Arm)
Percentage of participants with local regrowth within 2 years of TNT
Measured: Up to 2 years after TNT
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Oct 2025
- Study startOct 2026 (estimated)
- Primary completionMay 2028 (estimated)
- Study completionDec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Rectal AdenocarcinomaStudies of the same condition, open and under way.
- More trials run by University of California, DavisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of California, Davis
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Ankit Sarin, MD, Principal investigator, University of California, Davis
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07209215
- Sponsor's protocol ID
- UCDCC322
- Other IDs
- P30CA093373, NCI-2026-00131
- Acronym
- ULTIMATE
- Status last verified
- Aug 2026
- First submitted
- 30 Sep 2025
- Last updated
- 5 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- ULtra sensiTive ctDNA-Informed Management eArly-stage recTal cancEr (ULTIMATE)
- ClinicalTrials.gov ID
- NCT07209215
- Acronym / sponsor ID
- ULTIMATE / UCDCC322
- Conditions
- Rectal Adenocarcinoma, Rectal Cancer, Early-stage Rectal Cancer, Locally Advanced Rectal Adenocarcinoma
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- University of California, DavisUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- Oct 2026 (estimated)
- Primary completion
- May 2028 (estimated)
- Study completion
- Dec 2028 (estimated)
- First posted
- 6 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a phase 2 pragmatic study to examine the utility of ctDNA-informed treatment management for participants with early-stage rectal cancer using the Signatera Genome assay. The primary aims are to 1) assess pathologic complete response (path CR) in the ctDNA informed management arm; 2) assess pathologic complete response (path CR) in the post total neoadjuvant therapy (TNT) standard of care (SOC) surgery arm; and 3) assess disease free survival (DFS) in the ctDNA informed management arm.
Detailed description
Two cohorts of participants will be enrolled: Cohort A (participants appropriate for receiving TNT) and Cohort B (TNT already performed at UC Davis Health or externally). At Time A after TNT is completed and based on ctDNA assay results, the clinical decision will be made to put participants into one of two arms: the ctDNA informed management arm (Watchful Waiting [WW] surveillance) or the post TNT SOC surgery arm; participants will be monitored for ctDNA positivity for up to 5 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| ctDNA informed management arm (Watch and Wait surveillance) | Experimental | Drug: Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT) |
| Post TNT SOC surgery arm | Experimental | Drug: Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Tumor tissue histologically confirming rectal adenocarcinoma that is available for Natera ctDNA assay.
- Cohort A only: Patients appropriate for receiving TNT including chemotherapy and chemoradiation.
- Cohort B only: TNT must have included at least 4 cycles of CAPEOX or 6 cycles of FOLFOX and at least 45 Gy in 25 fractions to the pelvis during chemoradiation.
- Patients ≥18 years of age at time of consent.
- Ability to understand and willingness to sign the informed consent form (ICF).
Key exclusion criteria (4 listed)
- Prior treatment for rectal cancer, except for cohort B.
- Evidence of distant metastatic disease on staging imaging (CT chest with abdominopelvic imaging by CT or MRI) within 8 weeks of enrollment.
- Patients on hemodialysis.
- Any condition that in the opinion of the investigator would interfere with the participant's safety or compliance while on trial
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT)Use of Signatera Genome ultra-sensitive ctDNA blood test post-total neoadjuvant therapy (TNT) for ctDNA-informed treatment management of early-stage rectal cancer. | Drug | Post TNT SOC surgery arm, ctDNA informed management arm (Watch and Wait surveillance) |
Primary outcome
Pathologic complete response (pathCR) rate (ctDNA Informed Management Arm)
Time frame: Up to 2 years after TNT
Percent of participants with local regrowth within 2 years of total neoadjuvant therapy (TNT)
Pathologic complete response (pathCR) rate (Post TNT SOC Surgery Arm)
Time frame: Up to 2 years after TNT
Percent of participants with local regrowth within 2 years of TNT
Disease-free survival (DFS) rate (ctDNA Informed Management Arm)
Time frame: Up to 2 years after TNT
Median interval from first date of TNT to the first occurrence of locoregional failure, distant recurrence, a new invasive colorectal primary cancer.
1 secondary outcome
Frequency of local regrowth (ctDNA Informed Management Arm)
Time frame: Up to 2 years after TNT
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Aug 2026.
Related trials for Rectal Adenocarcinoma
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
RecruitingPhase 1
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Metastatic Solid Tumors
Active, not recruitingPhase 2
Perioperative Cadonilimab (AK104) in Locally Advanced MSI-H/dMMR Gastric or Gastroesophageal Junction and Colorectal Adenocarcinoma
MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
Active, not recruitingPhase 1
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Breast Cancer, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ankit Sarin, MD principal investigator
University of California, Davis
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT) in people with Rectal Adenocarcinoma and Rectal Cancer, run by University of California, Davis at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Office of Clinical Research (916-382-6970, OCRReferral@health.ucdavis.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pathologic complete response (pathCR) rate (ctDNA Informed Management Arm) (time frame: Up to 2 years after TNT). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Aug 2026.